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Clarithromycin Induced Digoxin Toxicity: Case Report and Review
N. Kiran, S. Azam, S. Dhakam
Cardiology Division, Department of Medicine, The Aga Khan University, Karachi.

With the advent of newer broader spectrum
macrolides, a rapid surge in their use has been noticed in
Pakistan. Interaction between macrolide antibiotics and
other commonly used medications can be life threatening.
We report a case of clarithromycin interaction with warfarin
and digoxin leading to digoxin toxicity.

Case Report
A 56 year-old woman with history of severe rheumatic mitral stenosis and atrial fibrillation, was being treated with digoxin 0.25mg and warfarin 3mg daily for the past
five years. Patient's target international normalized ratio
(INR) was being maintained between 2.0 and 3.0. She presented to our institution with fever and cough for 5 days.
Two days prior to presentation, she was started empirically
on clarithromycin 500 mg twice daily by her primary care
physician for presumed community acquired pneumonia.
Her chest X-ray on admission was abnormal for left lower
lobe pneumonia. Patient was started on intravenous ampicillin/clavulanic acid 1.2 gm every eight hours and clarithromycin was also continued. Initial electrocardiogram
(EKG) showed atrial fibrillation with ventricular rate of
70/minute with minor lateral T wave abnormalities
(Figure 1).
Two days later patient developed profound weakness
associated with nausea, vomiting, dizziness and dyspnea.
On examination pulse rate was 40/minute. Another 12 lead
EKG done showed underlying atrial fibrillation with complete heart block, junctional escape rhythm and multifocal
PVCs with fixed coupling interval (Figure 2). Laboratory
results revealed digoxin level of 8.7 ng/ml (therapeautic
range=1.0-2.6) and an international normalized ratio (INR)
of 3.97 (2.0-3.0). Patient was shifted to coronary care unit
and all medications were discontinued except
ampicillin/clavulanic acid. Due to nonavailability of digoxin binding fragments only a temporary pacemaker was
inserted to increase the heart rate. Her heart rhythm returned
to baseline (atrial fibrillation) after 48 hours with decrease
in digoxin level to 3.0 ng/ml. The patient was finally discharged on day 7 with a digoxin level 1.6 ng/ml and a plan
to undergo mitral valve replacement.

Discussion
Interaction between macrolide antibiotics and other
commonly used medications is now a frequent occurrence.
One of the most likely explanations is the property of
macrolide antibiotics, especially erythromycin, to inhibit

cytochrome CYP450 hepatic microsomal enzyme system,
particularly CYP1A2 and CYP3A4 isoenzymes.1-3 Introduction
of newer macrolides with structural modifications resulted in
compounds with not only varying antibacterial activity but
also variability in their potential for interactions with other
drugs.4 Many of the macrolides are metabolized by
CYP3A4 to metabolites which form complexes with heme
(iron) molecules of the cytochrome, causing CYP3A4 to
lose its catalytic ability resulting in elevated serum levels of
drugs cleared by the hepatic CYP450 oxidizing system.5,6
Ten percent of population on chronic digoxin therapy convert upto 40% of ingested digoxin to inactive digoxin reduction products (DRPs) due to action of Eubacterium
lentum, an anaerobic bacillus which is part of normal gut
flora. It has been suggested that macrolide antibiotics, especially erythromycin and possibly clarithomycin alter the gut
flora by decreasing Eubacterium Lentum in the gut, thereby
reducing the conversion of digoxin to DRPs6-8 and thus
increasing serum digoxin level leading to toxic effects and
increased morbidity.
To our knowledge, there have been case reports of
clarithromycin induced digoxin toxicity but only one report
of clarithromycin induced digoxin toxicity and concomitant
warfarin interaction.6,9,10 Increased digoxin levels secondary to concomitant adminstration of erythromycin or clarithromycin presumably occured due to inhibition of
Eubacterium lentum within the gut flora, which is now
known to be principally responsible for the conversion of
digoxin to DRPs in the gut, leading to increased serum
digoxin level as described above.6,7,11 Another possible
mechanism of clarithromycin and digoxin interaction is
reduction of renal excretion of digoxin. It is suggested that
P-glycoprotein plays an important role in the renal secretion
of digoxin, and that clarithromycin can decrease renal
digoxin excretion by inhibiting P-glycoprotein-mediated
transport.12 Digoxin toxicity was reported 3-17 days after
the institution of clarithromycin (8.1+4.8 day, n = 9). The
wide variation in the time required for the appearance of
toxicity may imply the different mechanisms involved in
each case.13
The macrolide antibiotics, also interact with the
commonly prescribed anticoagulant warfarin, which,
among other drugs is metabolized by the CYP450 system
with predominant involvment of CYP3A4.4,6 As the therapeutic range of warfarin is narrow, warfarin treatment needs
to be monitored carefully with dose reduction when concomitant treatment with macrolides is instituted.
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In this case we have described potential drug interaction between clarithromycin, digoxin and warfarin. Patient
mentioned in this case was maintaining her INR between
the desired range of 2.0-3.0 without any problem on
3mg/day of warfarin. After four days of therapy with clarithromycin, she developed life threatening complete heart
block secondary to elevated levels of digoxin and an INR
beyond therapeautic range which increased her risk of hemorrhage. There has been a case reported which described
similar interactions between these three drugs.6
Almost all antibiotics can potentiate the effects of
warfarin by inhibiting its hepatic metabolism.
Erythromycin-warfarin interaction has shown that erythromycin can markedly elevate the prothrombin time by inhibition of CYP450 system.4,6 Erythromycin and troleandomycin have the highest affinity for CYP3A4 isoenzyme
and therefore the strongest ability to inhibit substrate breakdown. Clarithromycin has a lower affinity for cytochrome
system, leading to less significant interactions with substrates
of CYP3A4.7 Since clarithromycin potentiates the effect of
warfarin, careful monitoring of INR is warranted. Two case
reports suggest that like erythromycin, clarithromycin, by
inhibiting hepatic cytochrome system, can lead to potential-

ly high risk of hemorrhage by increasing the serum warfarin level.3,6
Patient presented had been compliant with the prescribed doses of digoxin and warfarin for years without any
problems. Introduction of clarithromycin to her regimen
exposed her to serious adverse drug interactions between
these drugs with the development of life threatening complete heart block and increased INR with potential risk of
hemorrhage. Therefore we highlight serious drug interactions of commonly prescribed antibiotics in patients on long
term digoxin and warfarin therapy.
In this case we have described potential interactions
between drugs commonly used in clinical practice with the
development of life threatening adverse reactions. This case
gives a better perspective of the adverse drug interactions
which can occur in patients on long term digoxin and warfarin with introduction of macrolide antibiotic, clarithromycin. Prescribing physicians should be aware of possible drug interactions when starting a new drug in patients
on chronic drug therapy, thus preventing prolonged unnecessary hospitalizations and life threatening complications.
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